BioStock: Lipum has wind in its sails for phase I

During the first half of the year, Lipum made many important advances in preparations for the start of the first clinical study with the drug candidate SOL-116. The toxicology and safety programme was successfully completed, and Lipum's development work was also strengthened through recruitments and several new collaborations. The goal is to submit a clinical trial application and then start the clinical phase I study during the autumn, says CEO Einar Pontén in an interview with BioStock.

Read the interview with Lipum's CEO Einar Pontén at biostock.se:

https://www.biostock.se/en/2022/08/lipum-has-wind-in-its-sails-for-phase-i/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/